The in-vitro activity of Ro 17-2301, a new monobactam, compared with other antimicrobial agents

Research output: Contribution to journalArticle

Standard

The in-vitro activity of Ro 17-2301, a new monobactam, compared with other antimicrobial agents. / Wise, R; Andrews, J M; Piddock, L J.

In: Journal of Antimicrobial Chemotherapy, Vol. 15, No. 2, 02.1985, p. 193-200.

Research output: Contribution to journalArticle

Harvard

APA

Vancouver

Author

Bibtex

@article{549289bf9fb8459fafaefbe8229ed01a,
title = "The in-vitro activity of Ro 17-2301, a new monobactam, compared with other antimicrobial agents",
abstract = "The susceptibility of 554 recent clinical isolates and known resistant bacterial strains to the new monocyclic beta-lactam Ro 17-2301 were studied and compared to that to other beta-lactams (including aztreonam and temocillin) and gentamicin. Ro 17-2301 had a high degree of activity against the Enterobacteriaceae (MIC90 less than or equal to 0.25 mg/l) being similar or slightly more active than aztreonam and ceftazidime. Strains of Acinetobacter spp. (MIC90 16 mg/l). Haemophilus influenzae strains (including beta-lactamase producers) were more susceptible (MIC90 0.5 mg/l) than those of Neisseria gonorrhoeae (MIC90 4 mg/l); against these latter two groups of isolates aztreonam was more active (MIC90 0.12 mg/l). Both aztreonam and Ro 17-2301 had little activity against Gram-positive cocci with the exception of Streptococcus pneumoniae for which the MIC90 of RO 17-2301 was 16 mg/l. Ro 17-2301 had modest activity against Bacteroides fragilis. The MBC of Ro 17-2301 was very similar to the MIC and the addition of human serum had little effect on the amount of the compound. The mean serum protein binding was 26.3%. A study of the penicillin binding protein affinity of Ro 17-2301 in a strain of Escherichia coli showed PBP 3 to be the primary target. The morphological response to exposure to Ro 17-2301 was filamentation followed by lysis after prolonged exposure.",
keywords = "Anti-Bacterial Agents, Aztreonam, Bacteria, Bacterial Proteins, Carrier Proteins, Culture Media, Drug Resistance, Microbial, Gentamicins, Hexosyltransferases, Lactams, Microbial Sensitivity Tests, Muramoylpentapeptide Carboxypeptidase, Penicillin-Binding Proteins, Peptidyl Transferases",
author = "R Wise and Andrews, {J M} and Piddock, {L J}",
year = "1985",
month = feb,
language = "English",
volume = "15",
pages = "193--200",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",
publisher = "Oxford University Press",
number = "2",

}

RIS

TY - JOUR

T1 - The in-vitro activity of Ro 17-2301, a new monobactam, compared with other antimicrobial agents

AU - Wise, R

AU - Andrews, J M

AU - Piddock, L J

PY - 1985/2

Y1 - 1985/2

N2 - The susceptibility of 554 recent clinical isolates and known resistant bacterial strains to the new monocyclic beta-lactam Ro 17-2301 were studied and compared to that to other beta-lactams (including aztreonam and temocillin) and gentamicin. Ro 17-2301 had a high degree of activity against the Enterobacteriaceae (MIC90 less than or equal to 0.25 mg/l) being similar or slightly more active than aztreonam and ceftazidime. Strains of Acinetobacter spp. (MIC90 16 mg/l). Haemophilus influenzae strains (including beta-lactamase producers) were more susceptible (MIC90 0.5 mg/l) than those of Neisseria gonorrhoeae (MIC90 4 mg/l); against these latter two groups of isolates aztreonam was more active (MIC90 0.12 mg/l). Both aztreonam and Ro 17-2301 had little activity against Gram-positive cocci with the exception of Streptococcus pneumoniae for which the MIC90 of RO 17-2301 was 16 mg/l. Ro 17-2301 had modest activity against Bacteroides fragilis. The MBC of Ro 17-2301 was very similar to the MIC and the addition of human serum had little effect on the amount of the compound. The mean serum protein binding was 26.3%. A study of the penicillin binding protein affinity of Ro 17-2301 in a strain of Escherichia coli showed PBP 3 to be the primary target. The morphological response to exposure to Ro 17-2301 was filamentation followed by lysis after prolonged exposure.

AB - The susceptibility of 554 recent clinical isolates and known resistant bacterial strains to the new monocyclic beta-lactam Ro 17-2301 were studied and compared to that to other beta-lactams (including aztreonam and temocillin) and gentamicin. Ro 17-2301 had a high degree of activity against the Enterobacteriaceae (MIC90 less than or equal to 0.25 mg/l) being similar or slightly more active than aztreonam and ceftazidime. Strains of Acinetobacter spp. (MIC90 16 mg/l). Haemophilus influenzae strains (including beta-lactamase producers) were more susceptible (MIC90 0.5 mg/l) than those of Neisseria gonorrhoeae (MIC90 4 mg/l); against these latter two groups of isolates aztreonam was more active (MIC90 0.12 mg/l). Both aztreonam and Ro 17-2301 had little activity against Gram-positive cocci with the exception of Streptococcus pneumoniae for which the MIC90 of RO 17-2301 was 16 mg/l. Ro 17-2301 had modest activity against Bacteroides fragilis. The MBC of Ro 17-2301 was very similar to the MIC and the addition of human serum had little effect on the amount of the compound. The mean serum protein binding was 26.3%. A study of the penicillin binding protein affinity of Ro 17-2301 in a strain of Escherichia coli showed PBP 3 to be the primary target. The morphological response to exposure to Ro 17-2301 was filamentation followed by lysis after prolonged exposure.

KW - Anti-Bacterial Agents

KW - Aztreonam

KW - Bacteria

KW - Bacterial Proteins

KW - Carrier Proteins

KW - Culture Media

KW - Drug Resistance, Microbial

KW - Gentamicins

KW - Hexosyltransferases

KW - Lactams

KW - Microbial Sensitivity Tests

KW - Muramoylpentapeptide Carboxypeptidase

KW - Penicillin-Binding Proteins

KW - Peptidyl Transferases

M3 - Article

C2 - 3980309

VL - 15

SP - 193

EP - 200

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - 2

ER -